119 results about "Acetylcysteine" patented technology

Provided herein are compositions and methods for treating patients with Usher syndrome associated retinitis pigmentosa (UARP) comprising identifying that the subject has UARP and administering to the animal or human an effective amount of an N-acetylcysteine amide (NACA) sufficient to protect vision and inhibit degradation of Ellipsoid Zone (EZ) area and retinal sensitivity. In one example, the NACA formulation is doses at 50, 100, 200, 201, 210, 225, 250, 275, 300, 350, 400, 450, 500, 600, 700, 750, 800, 900, or 1,000 mg / day.

The invention relates to the technical field of livestock and poultry breeding, in particular to a goat hybridization breeding method capable of achieving complete-cycle nutrition enhancement. The core of the method is that systematic nutrition intervention runs through the whole breeding process. Before hybridization, performing differential nutrition pretreatment on the parents for 60 days: feeding the female parents with a breeding nutrition enhancer added with components such as D-chiro-inositol and N-acetylcysteine, and supplementing sperm motility enhancer containing acetylated L-carnitine and ergothioneine to the male parents. In the gamete treatment stage, the oocytes are subjected to in-vitro maturation culture in a special culture solution containing components such as D-chiro-inositol and a growth differentiation factor 9; after the sperms are subjected to gradient centrifugal screening, completing in-vitro fertilization in an optimized fertilization culture solution; after the embryos develop into blastocysts in the sequential culture system, carrying out laparoscopic transplantation, and carrying out staged precise nutrition culture on the pregnant ewes. According to the method, through multi-level nutrition enhancement, the reproductive capacity of the goats and the growth performance of offspring are effectively improved.

The invention belongs to the technical field of biology, and relates to a bronchoalveolar lavage fluid (BALF) preserving fluid, a kit and a cytological test method. The preservation solution is composed of TCEP, N-acetylcysteine, EDTA.2Na, trehalose, Proclin300, methanol, sodium chloride and HEPES, and all the components have a synergistic effect to achieve sample viscosity removal, oxidation resistance, corrosion prevention, cell protection and pH stabilization. The preserving fluid is suitable for morphological observation and nucleic acid detection of BALF cells, and can stably preserve samples at room temperature and maintain completeness of cell membranes and clear morphological structure. The kit comprises two preparations which are mixed to form a working solution, and the working solution can be directly used for sample preservation on a sampling site. The cytological test method comprises the steps of sample collection, preservation, centrifugal slide preparation, Wright-Giemsa staining and microscopic observation. Experimental results show that preservation solutions of different formulas are compatible with a chromosome system, the cell morphology is kept stable within 3 days, the dyeing effect is good, and it is proved that the preservation system can remarkably improve the preservation stability and detection reliability of BALF samples and is suitable for cytology and molecular diagnosis application of lower respiratory diseases.

Described herein are compositions and methods for treating lung damage associated with cancer therapy, for example radiation-induced lung damage or chemotherapy-induced lung damage. Lung damage may be treated by administering heparin, optionally formulated with or administered concurrently with N-acetylcysteine. The compositions may be nebulized and administered via inhalation to treat lung damage.

A method for separately quantifying N-acetylcysteine and glutathione in brain tissue includes administering N-acetylcysteine to a subject, acquiring a first magnetic resonance spectroscopy signal from a region of brain tissue of the subject, the first magnetic resonance spectroscopy signal comprising a cysteine β-proton signal, acquiring a second magnetic resonance spectroscopy signal from the region of brain tissue, the second magnetic resonance spectroscopy signal comprising an N-acetyl proton signal, and determining a concentration of N-acetylcysteine in the region of brain tissue based on the N-acetyl proton signal and determining a concentration of glutathione in the region of brain tissue based on a difference between the cysteine β-proton signal and the N-acetyl proton signal.

The invention provides a special culture medium for prostate cancer organoid and a culture method thereof, and belongs to the technical field of biological medicines. The special culture medium for the prostatic cancer organoid is composed of a basic culture medium and a culture additive, and the basic culture medium does not contain exogenously added Noggin recombinant protein and R-spondin recombinant protein. The culture additive is prepared from a basic fibroblast growth factor, a keratinocyte growth factor, a fibroblast growth factor 10, insulin, a p38MAPK signal channel inhibitor, an insulin-like growth factor 1, B27, nicotinamide, N-acetylcysteine, hydrocortisone, a ROCK kinase inhibitor, retinoic acid, interleukin 6, prostaglandin E2, a eriocin and androgen. According to the special culture medium for the prostatic cancer organoid, the culture success rate is increased while the cost is reduced.

The application discloses a kind of inhaled acetylcysteine solution clinical use hydrogen sulfide rapid detection device and method, the device includes gas detector, atomizer and atomizing cup, the atomizer is connected by first pipeline seal the detection end of gas detector, the first pipeline is sealed by sealing membrane with atomizing cup is set.The method mainly includes obtaining the concentration of the gas detector in the preset time within the preset time period, the preset time period includes multiple detection times, the time interval between each detection time is equal;With detection time as abscissa, concentration as ordinate, draw curve, calculate the total amount of hydrogen sulfide gas detection curve area.The different time values of hydrogen sulfide can reflect the release characteristics of the drug in clinical use, and the total amount of hydrogen sulfide calculated according to the formula can reflect the situation of hydrogen sulfide in the preparation, which can provide technical guidance for the clinical use of inhaled acetylcysteine solution.

The invention relates to the technical field of biological medicines, in particular to a maintenance solution for culturing influenza viruses as well as a preparation method and application of the maintenance solution. The maintenance liquid comprises a basic culture medium and effective components, the effective components comprise amino acids, vitamins, salts and a virus nutrition enhancer, and the virus nutrition enhancer is a microorganism induced culture extract. The extract is prepared by inoculating fermentation microbial bacteria, performing induced culture through a plant induction factor extract containing American ginseng, polygonum cuspidatum and golden cypress, and then performing autolysis and enzymolysis in the presence of compound metabolic regulatory factors, namely trichosalix A and N-acetylcysteine. The maintenance fluid can significantly enhance host cell metabolism, inhibit cell antiviral response and delay cell apoptosis after infection, so that the culture yield and process stability of influenza viruses are significantly improved under the condition of no dependence on serum.

The invention relates to the use of scyllo-inositol alone or in combination with other active ingredients including the compound N-acetylcysteine or a derivative thereof to support cognitive health in a subject that takes the product or combination product. The compositions, which are inclusive of oral dosage forms such as tablets or capsules, are provided to the subject which is inclusive of humans or other mammals such as dogs or cats or other animals in need of cognitive improvement. The combination product(s) break up amyloid beta aggregates and promote the clearance of amyloid beta fibrils from the glymphatic system as well as the treatment of disease and conditions that are acerbated by free radicals.

This invention discloses a composite dewatering agent for sludge dewatering in wastewater treatment and its preparation method, belonging to the field of sludge treatment technology. The composite dewatering agent comprises, by weight, the following raw materials: 30-50 parts chitosan-acetylcysteine-modified coal gangue, 20-40 parts cationic starch-modified fly ash fiber, and 1-3 parts nonionic surfactant. The composite dewatering agent of this invention, comprising chitosan-acetylcysteine-modified coal gangue, cationic starch-modified fly ash fiber, and nonionic surfactant, significantly improves the sludge dewatering rate through the synergistic effect of each component, utilizing multiple mechanisms such as charge neutralization, adsorption bridging, and the release of bound water through extracellular polymer destruction. This invention fully utilizes solid waste and natural materials in the preparation of the composite dewatering agent, achieving resource utilization of solid waste while avoiding residual pollution from traditional polyacrylamide flocculants and reducing environmental hazards.

The invention relates to a composition comprising N-acetylcysteine (NAC) for use in the prevention and / or treatment of at least one adverse effect of a chemotherapy in the treatment of cancer. It is characterized in that it further comprises vitamin B12 and / or a combination of vitamins B1, B2 and B3. The invention more particularly relates to the use of said composition for the prevention and / or treatment of chemo-induced nociceptive and / or neuropathic pain.

A composition for relieving hangovers and protecting the liver, made from the following raw materials in the indicated weight ratios: 3-20 parts of kudzu root extract, 2-20 parts of Japanese raisin tree fruit extract, 1-12 parts of N-acetylcysteine, 1-12 parts of L-ornithine, 1-15 parts of L-glutamine, 0.2-8 parts of glycyrrhetinic acid glycyrrhiza extract, 0.05-5 parts of curcumin, 0.005-0.5 parts of piperine, 0.5-10 parts of vitamin C, 0.01-2 parts of B vitamins complex, 0.1-8 parts of electrolyte salts, and 1-25 parts of honey or oligosaccharides.

The invention provides a lung squamous cell carcinoma organoid culture medium and a culture method. The lung squamous cell carcinoma organoid culture medium is prepared from the following components: R-spondin-1, Noggin, EGF (Epidermal Growth Factor), FGF10 (Fibroblast Growth Factor), FGF7 (Fibroblast Growth Factor), A83-01, Y-27632, Nicotinamide, Insulin, B27 Supplement, N-Acetylcysteine, Alpisib, GlutaMAX, primary cell antibiotics and the like. The lung squamous cell carcinoma organoid culture medium can be used for efficiently culturing lung squamous cell carcinoma tissues and successfully obtaining organoid, the formed organoid is highly similar to primary lung squamous cell carcinoma tissues in cell type, polarity and spatial hierarchical structure, and the micropathologic characteristics of tumors are truly reproduced. And the organoid can be stably passaged for a long time, so that an ideal and reliable preclinical model is provided for pathogenesis research, personalized drug screening and novel therapy development of lung squamous cell carcinoma.

Compositions for the treatment of acute manifestations because of oxidative injury by reactive oxygen species (ROS) and chronic development of fibrosis are provided. Compositions of the present invention include perfluorocarbon, hydrogen and oxygen gas, N-acetylcysteine, and glycine to counter robust oxidative responses unleashed following injury from both mechanical and non-mechanical conditions. Methods are also disclosed for delivery to challenging locations (olfactory cleft, spinal canal) and in hostile conditions (post trauma brain, spine, and upper and lower airways), with the invention's products "calming" inflamed tissue by neutralizing ROS in both acute and later complications. Active pharmaceutical ingredient(s) can also be employed to provide both acute and chronic benefit, and such active ingredients themselves can be augmented by the composition, enabling increased drug uptake and oxygenation. The present invention provides broad relief in many conditions for both human and companion subjects.

A supplement, and a method of treatment utilizing the supplement to elicit positive responses in a patient with neurological conditions is disclosed. The supplement comprises four components: N-acetylcysteine, glycine, choline, and biotin. In the preferred embodiment for treating adult patients, the effective supplement daily dosage comprises at least 1500 mg of glycine, 1500 mg of N-acetylcysteine, 1000 mg of choline, and 1000 μg of biotin. In another embodiment for treating pediatric patients, the supplement may comprise an effective supplement daily dosage of at least 500 mg of glycine, 500 mg of N-acetylcysteine, 250 mg of choline, and 250 μg of biotin. In a method embodiment, regular daily dosages of a supplement comprising over 1 g total of the four components are administered, resulting in improved outcomes among patients with cognitive impediments.

The invention discloses an additive formula capable of remarkably reducing the proportion of G0F-N in antibody glycosylation, and the additive formula comprises 2-mercaptoethanol, hydrocortisone, galactose, mannose, 1, 4-diaminobutane dihydrochloride and N-acetylcysteine. The use method comprises the following steps: preparing 1 mM mother liquor from 2-mercaptoethanol by using original liquid, preparing 1 mM mother liquor from hydrocortisone by using absolute ethyl alcohol, preparing 200 g / L mother liquor from galactose by using ultrapure water, preparing 100 g / L mother liquor from mannose by using ultrapure water, preparing 1 g / L mother liquor from 1, 4-diaminobutane dihydrochloride by using ultrapure water, and preparing 1 g / L mother liquor from N-acetylcysteine by using ultrapure water. Wherein 2-mercaptoethanol and hydrocortisone are used as an additive group 1 for combined use, galactose and mannose are used as an additive group 2 for combined use, and 1, 4-diaminobutane dihydrochloride and N-acetylcysteine are used as an additive group 3 for combined use. In the cell culture process, the additives are combined according to different concentrations to achieve the effect of remarkably reducing G0F-N in antibody glycosylation.

Provided herein are tablet(s) comprising N-acetylcysteine amide (NACA) and a NACA-acceptable, biocompatible excipient and optionally one or more pharmaceutically acceptable additives, binders, or fillers. Also provided are methods for making the tablets comprising N-acetylcysteine amide (NACA) and a NACA-acceptable, biocompatible excipient and optionally one or more pharmaceutically acceptable additives, binders, or fillers, e.g., comprising slugged tablets, wherein the slugged tablets have greater than 90, 91, 92, 93, 94, 95, 96, 97, 98, or 100% of the slugged tablets meet specifications; target width of 10 to 12 mm, or 11 mm; target weight of approximately 475 to 525 mg; and thickness range of approximately 4 to 6 mm, 4.5 to 5.5 mm or 5 mm. Pharmaceutical composition(s) in the form an oral tablet or capsule comprising N-acetylcysteine amide (NACA) for administration of the pharmaceutical composition to a human.

An immunomodulatory composition comprising an active agent, said active agent comprising acetylcysteine and beta-glucan.

The application discloses a method for improving the chromatographic separation degree of impurities A and B in acetylcysteine raw materials, and is characterized by the following steps: controlling the column temperature of a chromatographic column within a specific low temperature range of 15 DEG C plus or minus 2 DEG C, and using the difference between the distribution behaviors of impurities A and B between a stationary phase and a mobile phase at different temperatures to significantly improve the separation degree of the two impurities. When the column temperature is 15 DEG C, the separation degree of impurities A and B can reach 2.06, which is much higher than the pharmacopoeia standard, and the separation degrees under the conditions of 30 DEG C, 35 DEG C and 40 DEG C all fail to meet the standard. The application does not need to replace the chromatographic column, is simple and convenient to operate, low in cost, can stably meet the accurate quantification requirements of related substances in acetylcysteine raw materials, and has good popularization and application value.

This invention relates to the field of polypeptide derivative technology, specifically a method for preparing S-acetylglutathione in an aqueous system. The method involves dissolving 10% glutathione in water, adding 1-acetylimidazole, and reacting in controlled portions of 20-30 times, with 2-minute intervals, until the glutathione residue reaches 0.02%. The pH is adjusted to 3 with hydrochloric acid, and ethanol is added stepwise with seed crystals for crystallization. The mixture is then cooled to 4°C and stirred for 2 hours. After filtration, the product is washed with 60% ethanol to obtain S-acetylglutathione. This method does not use organic solvents, exhibits high selectivity, extremely low substrate residue, high crystallization efficiency, a product purity of 98.8%, and a yield of 90.9%. The process is simple, environmentally friendly, and suitable for industrial production.

The invention relates to the technical field of medicaments, in particular to an astragalus polysaccharide selenium compound capable of regulating tumor microenvironment and preparation thereof, and the astragalus polysaccharide selenium compound comprises the following components in parts by weight: modified nano GABA (gamma-aminobutyric acid) particles, spina date seed flavone extract, xylaria nigripes polysaccharide, N-acetylcysteine modified chitosan, vitamin B6, a trehalose stabilizer and natural menthol. According to the invention, the synergistic effect of stability improvement, delivery efficiency optimization and efficacy synergistic enhancement is formed through cooperation of the components instead of simple superposition of the components. Due to the slow release characteristic of the modified nano GABA particles, the concentration of GABA in a central nervous system is maintained within an effective therapeutic window, and a time window is provided for the synergistic effect of the spina date seed flavone extract and xylaria nigripes polysaccharide; the flavone extract inhibits the release of excitatory transmitters and reduces the action load of GABA (gamma-aminobutyric acid), so that a small amount of GABA can achieve an ideal regulation effect; the xylaria nigripes polysaccharide improves the sensitivity of nerve cells to GABA (gamma-aminobutyric acid), which is equivalent to the effect of amplifying the GABA.

Provided are a liquefying agent and the use thereof, and a nucleic acid detection system. The liquefying agent comprises a strong base, acetylcysteine, and 2-(N-morpholino)ethanesulfonic acid. In the liquefying agent, the concentration of the strong base is 0.2-1 mol / L; the concentration of the acetylcysteine is 3-300 mmol / L; and the concentration of the 2-(N-morpholino)ethanesulfonic acid is 2-5 mmol / L. By means of the synergistic effect of the strong base, acetylcysteine and 2-(N-morpholino)ethanesulfonic acid, the liquefaction time can be significantly shortened, thereby improving the efficiency and speed of treating viscous biological samples. Furthermore, the viscous biological samples treated with the liquefying agent can be directly used for nucleic acid amplification and have a long storage period. Long-term stability ensures the accuracy and reliability of nucleic acid detection, thereby enhancing the credibility of detection results.

The application discloses a medicine composition for promoting wound healing and a preparation method and application thereof. The medicine composition comprises the following components in parts by weight: 1-10 parts of hemoglobin molecules, 1-5 parts of lipoic acid, 0.1-1 part of acetylcysteine, and 40-80 parts of a solvent; the hemoglobin molecules comprise at least one cysteine part and at least one histidine part, wherein the cysteine part comprises an acetyl group or an ethyl maleoyl group, and the histidine part comprises a benzimidazole derivative group. The application applies lipoic acid and acetylcysteine to the external medicine composition of the hemoglobin molecules modified by acetyl groups or ethyl maleoyl groups in combination, effectively relieves the irritant reaction caused by the hemoglobin modification to the skin through the synergistic antioxidant and tissue protection effects, and thus improves the safety and applicability of the medicine composition in skin wound treatment, and the medicine composition is suitable for treating multiple types of wounds such as external injuries, burns, postoperative wounds and ulcer wounds.

The present application belongs to the field of cell biology, specifically by adding recombinant human DFF45 protein, Z-VAD-FMK, Cyclosporin A, bFGF, N-Acetylcysteine, regulating the activity and effect of apoptosis-specific nuclease, reducing the apoptosis rate of umbilical cord mesenchymal stem cells, and also can improve the proliferation effect of umbilical cord mesenchymal stem cells, the proliferation rate of umbilical cord mesenchymal stem cells is increased by 17.53%, and the apoptosis rate of umbilical cord mesenchymal stem cells by ordinary conventional culture method is reduced from 14.32% to 9.81%, effectively solving the core problem of stem cell proliferation attenuation, apoptosis rate increase in the existing culture technology, maintaining the biological activity and quality stability of stem cells in the long-term subculture process, providing reliable technical support and experimental basis for the large-scale culture, in vitro expansion and subsequent clinical transformation application of umbilical cord mesenchymal stem cells.

Methods for making and using hydrogels comprising therapeutic microparticle compositions are disclosed. Illustrative methods of the invention include methods of making a hydrogel composition, the method comprising combining at least 14% w / v of a non-ionic copolymer surfactant having the linear formula (C3H6OꞏC2H4O)x; microparticles comprising a polycaprolactone; and a therapeutic agent; such that the hydrogel composition is made. Embodiments of the invention further include compositions made by the methods disclosure herein as well as methods for using these compositions. For example, methods of the invention include disposing a composition in the ear of a subject being administered cisplatin, wherein amounts of the composition administered are sufficient to preserve hearing function in a mouse model of cisplatin ototoxicity.

Provided herein are tablet(s) comprising N-acetylcysteine amide (NACA) and a NACA-acceptable, biocompatible excipient and optionally one or more pharmaceutically acceptable additives, binders, or fdlers. Also provided are pharmaceutical composition(s) in the form an oral tablet comprising N-acetylcysteine amide (NACA), wherein the composition has a pharmacokinetic (PK) profile comprising mean plasma concentrations of NACA range from about 200 to 1200 ng / mL after administration of the pharmaceutical composition to a human.

1. Name of the designed product: packing box (acetylcysteine granules). 2. Use of the designed product: the designed product is used for packing acetylcysteine granules. 3. Design points of the designed product: combination of shape and pattern. 4. Picture or photo best indicating the design points: front view.

The application belongs to the technical field of biological medicine, and particularly relates to application of a METTL3 inhibitor in preparation of a medicine for treating drug-induced liver injury; the METTL3 inhibitor comprises STM2457 or JNJ64619178; the drug-induced liver injury is acetaminophen-induced acute liver injury. It is found for the first time that the METTL3 inhibitor STM2457 or JNJ64619178 has a significant curative effect on treatment of acetaminophen-induced drug-induced liver injury, STM2457 or JNJ64619178 can effectively alleviate acute liver tissue injury caused by acetaminophen, inhibit further apoptosis and necrosis of hepatocytes, help promote recovery of liver injury, and the treatment effect is better than that of a traditional medicine N-acetylcysteine, thus providing a new treatment means for acetaminophen-induced drug-induced liver injury and expanding the clinical application range of the inhibitor.

Presented herein are methods for making, isolating, and purifying N-acetylcysteine amide, (2R,2R′)-3,3′-disulfanediyl bis(2-acetamidopropanamide, diNACA), intermediates and derivatives thereof comprising: alternatively contacting cystine with methanol and a chlorinating reagent to form an organic solution containing L-cystine dimethylester dihydrochloride; combining dried or undried L-cystine dimethylester dihydrochloride with a triethylamine, an acetic anhydride, and an acetonitrile to form a di-N-acetylcystine dimethylester; mixing dried di-N-acetylcystine dimethylester with ammonium hydroxide to form a di-N-acetylcystine amide (diNACA); and separating dried di-N-acetylcystine dimethylester into N-acetylcysteine amide with dithiothreitol, triethylamine, and an alcohol.